Abstract
Preterm birth is a global health concern and continues to contribute to substantial neonatal morbidity and mortality despite advances in obstetric and neonatal care. The underlying aetiology is multi-factorial and remains incompletely understood. In this review, the complex interplay between the vaginal microbiome in pregnancy and its association with preterm birth is discussed in depth. Advances in the study of bacteriology and an improved understanding of the human microbiome have seen an improved awareness of the vaginal microbiota in both health and in disease.

Keywords Preterm birth · Pregnancy · Vaginal microbiome · Lactobacillus

Introduction
Preterm birth (PTB) is a multi-aetiological disease state that causes almost 1 million deaths each year making it the primary cause of mortality in children under 5 years of age worldwide [1]. Infection is thought to contribute to at least one third of these cases [2, 3]. Whilst systemic maternal infection and colonisation of the lower reproductive tract by known pathogens such as Trichomonas vaginalis and Chlamydia trachomatis have long been associated with increased risk of PTB, recent applications of molecular-based profiling methods have provided new insights into the role that microbe-host interactions in pregnancy play in shaping PTB risk [4, 5]. In this review, we examine the current evidence linking maternal microbiota composition and host response to high-risk PTB phenotypes.

Culture- and molecular-based profiling of microbial communities
Bacteriology in the late nineteenth and twentieth centuries was largely limited to the investigation of microorganisms that were easily amenable to isolation and culture outside of the human body. However, advances in microscopy quickly led to the realisation that human body niches were colonised by many different microbial morphotypes of a complexity that culture-based methods alone failed to capture. In the twenty-first century, the application of culture-free, molecular-based approaches such as high-throughput DNA sequencing techniques has provided a step change in our ability to rapidly and comprehensively characterise polymicrobial communities and has led to a greater appreciation of the vast numbers of bacteria, viruses, fungi and archaea that inhabit the human body [6]. The sum total of microorganisms present in a defined community is referred as the ‘microbiota’, whereas the ‘microbiome’ refers to the entire habitat, including the microbiota, their genomes and the surrounding environmental conditions [7].

Broadly, two sequencing-based strategies are commonly used to study the microbiota; ‘metagenomics’ and ‘metataxonomics’. The metagenome refers to the collection of genomes and genes from the members of a microbiota community and is obtained through shotgun sequencing of all of DNA present in a given sample [7]. Metataxonomics involves amplification and sequencing of specific, often short-length regions of microbial taxonomic marker genes. For bacteria, the 16S ribosomal RNA gene (16S rRNA) is most
commonly targeted, whereas the internal transcribed spacer (ITS) region is often used for characterisation of fungi. The bacterial 16S rRNA gene is composed of highly conserved regions and nine ‘hyper-variable’ regions (V1-V9). PCR primers designed to bind to the conserved regions permit amplification of the variable regions, which are generally diverse and distinctive thus facilitating classification of bacterial taxonomy to species, and in some cases strain level, by mapping the resulting sequences to existing 16S rRNA gene databases [8]. Accurate identification of bacterial species using metatranscriptomics is therefore prone to bias depending on the choice of amplification region, primer design and even the database that the sequence reads are mapped to. For example, the ‘conserved’ regions of the 16S rRNA gene are not fully conserved so PCR primers may selectively bind to some but not all bacterial DNA in the sample. Moreover, ‘hyper-variable’ regions will not always provide sufficient variability to distinguish between species, let alone strains of bacteria. Such issues are important to consider when examining and interpreting results of microbiota studies parti- cular in the context of studies focussed on the reproductive tract microbiota [9]. For example, the targeting of the V4 hyper-variable region, which is commonly used to examine the gut microbiota, gives poor resolution of Lactobacillus species, a key- stone commensal species of the cervicovaginal niche. Conversely, whilst the V1–V2 region differentiates Lactobacillus species well, universal primers may fail to amplify the important vaginal pathobiont, Gardnerella vaginalis, due to it having a less conserved sequence in the pre-V1 conserved region. Such difficulties can be overcome by careful design and use of degenerate PCR primers; however, it is important to recogni- se that rare, but physiologically important, taxa may be missed through selective amplification of high-abundance species.

In contrast to metatranscriptomic profiling, metagenomics approaches provide strain-level resolution through shotgun sequencing and bioinformatic assembly of microbial genomes, which can then be mapped and annotated using reference databases. Metagenomic sequencing avoids PCR bias and captures information of the collective genomes from all then constituents of the microbiome kingdom. The resulting information can be leveraged to provide insight into potential metabolic function in additional to compositional structure of the community under investigation. Disadvantages have historically included higher costs, greater computation burden and inability to detect rare or low-abundance taxa in low-biomass samples that are overwhelmed by DNA from host and highly abundant commensals. These issues are increasingly less of a concern as sequencing costs continue to fall and new methods for sample preparation and bioinformatics approaches are developed [10].

The vaginal microbiota in health and disease

The vaginal microbiota plays a key role in female genital tract health and disease [11]. Throughout a woman’s lifespan, the composition of the vaginal microbiota is shaped by both intrinsic and extrinsic factors. Prior to the menarche low levels of circulating oestrogen associate with a high-diversity micro- bial structure consisting of aerobic, anaerobic and enteric bacteria [12]. Menarche is associated with increasing circulating oestrogen levels which promote proliferation of vaginal epithe- lial cells and glycogen deposition, the breakdown products of which can be preferentially utilised by Lactobacillus spp. as a primary carbon source, favouring their dominance and leading to a fall in pH [13]. This acidic environment, enriched by bacteriocins and other antimicrobial compounds produced by Lactobacillus spp., results in a hostile mucosal microenviron- ment that they have evolved and adapted to thrive in, which is hostile to many other microbial species. In this way, Lactobacillus spp. are considered to be keystone members of the vaginal microbiome during a woman’s reproductive years and are often associated with states of health and protection against bacterial vaginosis (BV), pelvic inflammatory disease, candidiasis, sexually transmitted infections, HIV, HSV-2 and carcinogenic human papilloma virus [14–19].

The first application of next-generation sequencing–based approaches to characterise the bacterial component of the vagi- nal microbiota was published by Ravel et al. [15]. Using hierarchical clustering of relative abundance data derived from metatranscriptomic profiling of vaginal samples collected from asymptomatic women, they described five distinct vagi- nal community state types (CST). Four of these state types were dominated by Lactobacillus spp. (L. crispatus, L. gasseri, L. iners or L. jensenii, designated CST I, II, II and V respectively). The remaining CST, CST IV, was Lactobacillus spp. depleted and characterised by a highly diverse, polymicrobial community that compositionally resembled that of women with a clinical diagnosis of bacterial vaginosis. This schema was later modified to account for differ- ences within the Lactobacillus spp. deplete, high-diversity groups with CST IV-A, characterised by enrichment for Peptoniphilus and Prevotella species, and CST IV-B, characterised by a higher relative abundance of Atopobium and Gardnerella species and other taxa previously associated with bacterial vaginosis. Whilst other statistical methodolo- gies have since been used to classify vaginal microbiota pro- files (also referred to as ‘vagitypes’ or ‘vaginal microbial communities’), their compositional characteristics remain relatively consistent despite rarer vaginal microbial community types increasingly being reported (e.g. Bifidobacteria-dominated profiles).

Longitudinal profiling of vaginal microbiota has shown that whilst some women maintain a level of compositional stability throughout the menstrual cycle and at the time of menstruation,
falling oestrogen and progesterone, endometrial shedding and vaginal bleeding lead to dynamic shifts in composition, often characterised by reduced *Lactobacillus* sp. relative abundance, which recovers during the follicular phase of the cycle [20]. Pregnancy brings endocrine stability, a substantial increase in circulating oestrogen concentrations and an end to menstrual bleeding which favours *Lactobacillus* sp. dominance of the vaginal microbiota [21]. Several cohort studies have shown that healthy pregnant women with normal outcomes generally maintain a vaginal microbiota dominated by *Lactobacillus* spp. throughout the entire pregnancy. The shift towards *Lactobacillus* sp. dominance appears to occur early in pregnancy and is most dramatically observed in women of African ancestry. Following delivery, maternal oestrogen levels fall to menopausal levels, which, coupled with the passage of lochia, changes the vaginal environment resulting in decreased *Lactobacillus* spp. and a shift towards *Lactobacillus* spp. [21] depleted community structures that have been reported to persist for up to one year postpartum [22].

The vaginal microbiome and preterm birth

Intrauterine infection leading to PTB is widely hypothesised to be secondary to pathogen ascension from the vagina [23, 24]. In humans, this notion is supported by the similarity observed between bacterial species found in the placenta and fetal membranes (amnion and chorion) of PTB cases and those found in the vagina [25, 26]. The fact that histological chorioamnionitis is most frequently observed at the site of membrane rupture in the lower part of the uterus close to the cervix [27] and in twin pregnancies, where histological chorioamnionitis and microbial invasion of the amniotic cavity are most commonly observed in the presenting and first born twin further supports the notion [25, 28]. The process of ascending vaginal infection leading to PTB can also be readily replicated in a number of animal models [29–34].

Given this evidence, characterisation of the vaginal microbiota in women with PTB or preterm prelabour rupture of the membranes (PPROM) has gained increasing attention. As commonly occurs in burgeoning research areas, the earliest of these studies were limited by a lack of power and a lack of consideration of underlying aetiology, which lead to inconsistent reports of relationships, or lack thereof, between vaginal microbiota and PTB. In the earliest of such molecular-based studies of vaginal microbiota in PTB, Hyman et al. reported that bacterial diversity was greater in Caucasians with PTB but that species diversity was generally higher among African Americans [35]. In contrast, Romero et al. found no differences in bacterial taxa abundance or community state types between women delivering preterm or term; however, this cohort was almost entirely African American [36]. The concept that ethnicity is a strong determinant of the vaginal microbiome and its effect upon PTB rates was further developed in two studies from the Relman group in Stanford. The first in a mostly White population correlated *Lactobacillus*-depleted vaginal community state types with reduced gestational age at delivery and showed that risk for PTB was greater in women with high abundances of *Gardnerella* or *Ureaplasma* [22]. The subsequent study compared two populations, White women in California and Black women in Alabama, and showed that whilst *Lactobacillus* depletion and greater abundance of *Gardnerella* were more common in Black women, it represented a risk factor for PTB only in White women. *Lactobacillus crispatus* was found to be protective against PTB in both groups [37].

A study on a small group of nulliparous African American women reported a trend between spontaneous PTB and lower vaginal bacterial diversity, although this was not statistically significant [38]. Similarly in a cohort of Black women, abundance of specific *Lactobacillus* species did not correlate to risk or protection from PTB, but a decrease in vaginal diversity was associated with PTB in African American women [39]. Recently, differences between bacterial taxa and PTB between African American and non-African American women have been explored [40]. Again, whilst more African Americans had reduced abundance of *Lactobacillus* species, this was only a significant risk factor for PTB in White women. This study also reported the identification of specific bacterial taxa that were significantly associated with spontaneous PTB, with a stronger effect observed in African American women. However, in this cohort, higher β-defensin-2 lowered the risk of spontaneous PTB in Black women.

As part of the integrative Human Microbiome Project, Fettweiss et al. compared the vaginal microbiome and cytokine profile between 45 women delivering preterm and 90 women delivering term of African descent, matched for age and income. Metaxonomic, metagonomic and cytokine analyses showed those delivering preterm had significantly lower levels of *Lactobacillus crispatus*, higher levels of BVAB1, *Sneathia amnii*, TM7-HI and a group of *Prevotella* species [41]. Women that delivered term were more likely to have *Lactobacillus crispatus* and decreased prevalence of *A. vaginae* and *G. vaginalis*. PTB was also associated with a vaginal cytokine profile richer in pro-inflammatory cytokines, including eotaxin, IL-1β, IL-6 and MIP-1β.

European studies have tended to comprise mostly of White women. In a study of women of European, Middle Eastern or Asiatic origin, an increased risk of PTB associated with *Lactobacillus iners* and a protective effect for *Lactobacillus crispatus* dominance was shown [42]. Similarly, we previously showed that in a UK population, *Lactobacillus iners* dominance at 16 weeks was significantly associated with both a short cervix and PTB before 34 weeks [43]. In contrast, *Lactobacillus crispatus* dominance was highly predictive of term birth. In this study, neither cervical shortening nor PTB
were associated with high-diversity community compositions; however, the prevalence of *Lactobacillus* depletion in our cohort was relatively low. The concept that the vaginal microbiota may be more important in relation to early preterm birth is supported by Canadian data from predominantly White European women who showed that the predominance of microbial profiles dominated by *Lactobacillus gasseri*/*Lactobacillus johnsonii*, *Lactobacillus crispatus*/*Lactobacillus acidophilus*, *Lactobacillus iners*/*Ralstonia solanacearum* or *Bifidobacterium longum*/Bifidobacterium breve is associated with a decreased risk of PTB before 34 weeks of gestation [44]. High-diversity compositions and the presence of BV-associated bacteria (e.g. *G. vaginalis*, *A. vaginae* and *Veillonellaceae bacterium*) were linked to an increased risk of early PTB.

Approximately 30–40% of PTB cases are preceded by PPROM [45]. Rupture of the fetal membranes provides an entry point for ascending microbes, but infection may be both a cause and a consequence of PPROM. Pathogenic vaginal bacteria may ascend and trigger inflammatory cascades, leading to remodelling of the cervix and fetal membranes. Following PPROM, ascending pathogens contribute to the development of chorioamnionitis and funisitis [46–48].

Four studies have examined the vaginal microbiota at the time of PPROM. These show that up to half of women who present with PPROM have a vaginal microbiota characterised by intermediate or low *Lactobacillus* sp. dominance and high diversity [49–52]. Our study found that in individual case samples sampled both before and after PPROM, about half of those with *Lactobacillus* sp. dominance prior to PPROM became dysbiotic post rupture, and that treatment with erythromycin further exacerbates vaginal dysbiosis, characterised by *Lactobacillus* sp. depletion and enrichment for potentially pathogenic bacteria [52]. In this cohort, vaginal dysbiosis was a risk factor for both chorioamnionitis and early onset neonatal sepsis. In a later prospective cohort study, we observed reduced *Lactobacillus* sp. abundance and high diversity in a quarter of women prior to PPROM, but in only 3% of women who delivered at term without membrane rupture [53]. PPROM associated with a shift towards higher diversity, predominately occurring during the second trimester, although a vaginal bacterial community dominated by any species other than *Lactobacillus* was associated with subsequent PPROM at all gestational time windows, including during the first trimester.

Progesterone is now commonly offered to women at risk of PTB particularly in the context of second trimester cervical shortening. In vitro studies have shown that progesterone inhibits inflammatory pathways in amnion and myometrium, reducing cytokine and prostaglandin production [54–56]. Therapeutic progesterone may reduce myometrial contractility, prevent cervical remodelling and increase levels of local antimicrobial proteins, so reducing the risk of PTB [54, 57–59]. A small study which randomised women to progesterone or cervical cerclage showed that whilst cerclage leads to increased levels of inflammatory cytokines in cervicovaginal fluid, progesterone has no effect [60]. Progesterone action similarly does not appear to act through modulation of the vaginal microbiota. In non-pregnant women, Borgdorff et al. found that both injectable progestin contraception and combined oral contraception (progestin and oestrogen) do not significantly alter the vaginal microbiota, but may increase the risk of HIV transmission [61–63]. We have shown that administration of progesterone to women with a short cervix in pregnancy does not lead to changes in the abundance of either *Lactobacillus iners* or *Lactobacillus crispatus*. We showed through longitudinal sampling of women receiving progesterone for a short cervix that *L. iners* dominance persisted and was associated with all women who subsequently delivered preterm. It is therefore likely that the mode of action of progesterone is non-microbial [43].

The management of women presenting with cervical shortening and exposed membranes in the second trimester is challenging. Without intervention, delivery usually follows within 2–3 weeks [64, 65]. Insertion of an emergency or rescue cervical cerclage prolongs gestation and improves birth weight and neonatal survival [66, 67]. However, the take home baby rate following rescue cerclage is only 50% and identifying which women would benefit from a rescue cerclage is challenging [65]. Although management remains contentious, many obstetricians would offer ‘rescue’ cervical cerclage in such cases provided there was no clinical evidence of established preterm labour or chorioamnionitis. Data suggests that a bimodal distribution of the gestational age of delivery in women offered rescue cerclage is due to the underlying aetiology of cervical dilation with a subset of women likely to deliver early because of subclinical infection [66]. Consistent with this, we recently reported in a small cohort of women presenting with a dilated cervix and exposed fetal membranes that reduced *Lactobacillus* sp. relative abundance was observed in 40% of cases prior to cerclage compared with 10% of gestational age-matched controls [68]. *Gardnerella vaginalis* was over-represented in women presenting with symptoms and those in whom rescue cerclage failed to usefully prolong pregnancy. The insertion of a rescue cerclage, which was using inert monofilament material, did not affect the underlying bacterial composition. These findings point towards at least two underlying aetiologies in women presenting with silent cervical dilatation prior to PPROM, one of which is linked to pathogen colonisation of the cervicovaginal niche and poor response to cervical cerclage, and another which includes a high proportion of women with genuine cervical mechanical abnormality, and who may respond well to cerclage.
Vaginal microbiota and background PTB risk

There exists a small background increase in the rate of PTB in women with untreated cervical intraepithelial neoplasia (CIN), but the principal risk of PTB relates to the degree of tissue destruction caused by a pre-pregnancy history of a large loop excision of the transformation zone of the cervix (LLETZ) or cone biopsy. In particular, there is a ‘depth-dependent’ relationship between depth of excision of cervical tissue and subsequent risk of PTB [69]. We have shown that in non-pregnant women, CIN associates with an increased prevalence of vaginal microbiota characterised by high diversity and low levels of Lactobacillus spp. and that increasing severity of CIN is associated with decreasing relative abundance of Lactobacillus spp. [70]. A subsequent study of a cohort of adolescent and young women with histologically confirmed, untreated CIN2 lesions showed that women with Lactobacillus-dominant vaginal microbiota at baseline are more likely to have regressive disease at 12 months [71]. Current evidence suggests that LLETZ and similar procedures may improve vaginal microbiota composition. Wiik et al. demonstrated a reduction in the relative abundance of non-Lactobacillus spp. following LLETZ procedures [72]. Similarly, a follow-up of women 3 months after LLETZ procedures for CINI/II demonstrated a shift towards Lactobacillus iners dominance of vaginal communities [73]. This data collectively highlights vaginal dysbiosis in women with CIN or a previous LLETZ as a possible causal factor for increased risk of PTB in these women. Whilst to the best of our knowledge no published studies of the effect of pregnancy upon the vaginal microbiota in women who have had LLETZ have been reported, we have, however, seen excellent outcomes in women with a prior LLETZ who are managed by surveillance of cervical length during pregnancy with targeted cervical cerclage [74]. The association between PTB and local cervical treatment may therefore be microbial as well as mechanical.

From compositional awareness to mechanistic understanding

The great majority of studies linking the vaginal microbiota have been essentially associative, with little or no focus upon mechanism. A consistent finding across most studies is the protective effect of Lactobacillus species, particularly L. crispatus. In addition to producing bacteriocins and other antimicrobial compounds, L. crispatus produces mainly d-lactate as its primary metabolic end product, which not only acts to maintain a low pH but also has been reported to inhibit activation of extracellular matrix metalloproteinase inducer (EMMPRIN), an activator of MMP-9 and so of collagen degradation [75]. L. crispatus also has beneficial immunomodulatory functions and can inhibit adhesion of other bacteria such as G. vaginalis to vaginal epithelial cells [76]. In contrast, the role of L. iners in the vaginal microbiota is less clear, since it can be detected in normal conditions as well as during vaginal dysbiosis and as mentioned earlier, a number of studies have identified dominance of vaginal microbiota by L. iners as a risk factor for preterm labour. A major difference between L. iners and L. crispatus is genome size. L. iners has an unusually small genome (ca. 1 Mbp compared with 3–4 Mbp) resulting in a lack of key functional metabolic genes. As a result, it seems to have evolved a level of tolerance to co-colonise alongside other vaginal bacteria, including potential pathogens, and is associated with a transitional state of vaginal microbiota composition compared with L. crispatus, which is highly exclusionary [77]. L. iners dominance of vaginal communities is also associated with activation of EMMPRIN, and mucin-degrading enzymes which disrupts the immune barrier [75]. It may therefore be the case that unlike L. crispatus, L. iners fails to prevent pathogen colonisation of the vagina during pregnancy and is therefore indirectly ‘causative’ of high-risk vaginal microbiota communities that associate with PTB or that its ability to coexist with pathobionts and pathogens means that it simply acts as a marker.

Several studies have now reported findings suggesting that one of the ways in which high-diversity vaginal microbiota may increase risk of PTB is through untimely activation of inflammatory pathways involved in the initiation of parturition. In one of the first of such studies, we showed that in women with cervical cerclage, the use of a braided suture material induces a persistent shift towards vaginal microbiome dysbiosis and activation of local inflammation accompanied by ultrasound evidence of premature cervical remodelling [78]. Analyses of retrospective data from multiple centres across the UK also showed that braided cerclages associate with a threefold increase in numbers of intraterine fetal deaths and a doubling in the rate of PTB compared with cerclage with monofilament suture, which had no significant impact upon the vaginal microbiota, cytokine concentrations or cervical changes. This evidence suggests a direct effect of microbiome-activated inflammation on the cervix developing as the pregnancy progresses. That concept is supported by the finding from our prospective studies of PPROM described earlier that in the majority of cases, PPROM is associated with a shift towards higher diversity occurring during the second or early third trimester, relatively close to the time of PPROM [53]. Fetal leukocyte telomere length is reduced at the time of normal term labour and is a marker for oxidative stress and fetal membrane senescence [79]. Fetal leukocyte telomere length is also reduced in PPROM compared with PTB without prior PPROM but is similar to term births, supporting the hypothesis that PPROM may be in part caused by oxidative stress–induced senescence. A range of factors, including
infection or inflammation, can lead to oxidative stress. Mechanical stress may also activate sterile inflammation within the fetal membranes, thus providing an attractive hypothesis for a final common pathway to membrane rupture in the context of both abnormal mechanical forces, the context of cervical mechanical damage, polyhydramnios or multiple pregnancy, or vaginal dysbiosis–driven inflammation within the vagina cervix and lower uterine segment [79].

**Evidence for an oral-placental microbiome axis in preterm birth**

Haematogenous spread of microbes and subsequent colonisation of the placenta have also been proposed as a potential secondary route of invasion and infection leading to PTB [80]. It has been suggested that the origin of these bacteria is the oral cavity [81] and oral-to-placental transmission of pathogens can be demonstrated in murine models [82, 83]. Further evidence for an oral-placental axis involved in PTB includes the identification of common oral pathogens (e.g. *Fusobacterium nucleatum,* *Dialister* spp., *Prevotella* spp., and *Porphyromonas gingivalis*) in the placenta of women with periodontal disease [84, 85], which is associated with increased risk of PTB [84, 86, 87]. However, interventions that improve periodontal health during pregnancy do not prevent PTB [88–90] and many bacterial species that were historically considered to be limited to the oral cavity are now recognised as being commonly observed members of the vaginal niche.

Regardless, a large amount of research effort over the last decade has been invested into work describing the existence of a placental microbiome that may influence pregnancy outcome. Controversy continues to plague research in this area, much of which appears to stem from definition of terms with some investigators considering that the term ‘microbiome’ should only be applied to microbial communities that have a well-described biological or physiological function (e.g. gut or vaginal microbiome) in host health. For example, the human gut microbiome plays a wide range of essential physiological functions including nutrient absorption, metabolism, maintenance of mucosal integrity and immunomodulation. The human vaginal microbiome plays important roles in protecting the vagina from overgrowth of pathogens and pathogens, and prevention of ascending pelvic inflammatory disease or chorioamnionitis. These two ‘microbiomes’ clearly have essential physiological functions. Aagaard et al. published the first study suggesting that the placenta contains a genuine microbiome composed of non-pathogenic microbe [91]. The placental microbiome profiles were most akin to the human oral microbiome, and differences were seen in women with a history of antenatal urinary tract infection in the first trimester, and with PTB. Metagenomic analysis implied a wide range of potential metabolic functions for these organisms. However, the total biomass of organisms suggested to be in the placenta was very low, which is inconsistent with an essential metabolic role. Further, some of the microbes identified in the placenta had previously only been reported in environments very dissimilar to the human placenta, such as soda lakes, alkaline and saline habitats, and marine environments. One organism purportedly associated with PTB was *Gloeobacter,* which is a genus of cyanobacteria (also known as blue-green algae), which obtain their energy through oxygenic photosynthesis.

Subsequent studies using a combination of culture-based, metagenomic and metataxonomic analyses have failed to identify a genuine placental microbiome in normal pregnancy. Lauder et al. compared placental samples from healthy deliveries with a matched set of contamination controls, and oral and vaginal samples from the same women [92]. Placental samples and negative controls contained very low and indistinguishable copy numbers of the 16S rRNA gene. Oral and vaginal swab samples had six orders of magnitude higher copy numbers. It was concluded that all of the bacterial DNA amplified from placental samples derived from environmental or reagent contamination and that results diverged radically in association with the kit used to purify the DNA. Similarly, Theis et al. used a combination of cultivation, quantitative real-time PCR, 16S rRNA gene sequencing and metagenomics to study placentas from a cohort of women who had been delivered by Caesarean-section without labour at term [93]. They also concluded that a normal resident microbiota could not be identified in the human placenta and found no difference in microbiota between placental samples and background technical controls. Recently, Goffau et al. performed metagenomic and metataxonomic analysis to determine whether pre-eclampsia, small for gestational age infants or spontaneous PTB were associated with bacterial DNA in the placenta [94]. No bacteria were found in most placental samples, from either complicated or uncomplicated pregnancies. Almost all signals were related either to the acquisition of bacteria during labour and delivery, or to sources of laboratory contamination. The exception was *Streptococcus agalactiae* (group B streptococcus), for which non-contaminant signals were detected in 5% of samples collected. It therefore seems highly unlikely that there is genuine consistent and physiological relevant normal microbiome within the human placenta.

It does seem likely, however, that some cases of spontaneous preterm labour, particularly those associated with chorioamnionitis, harbour detectable bacteria within the placenta. A large recent UK study of 400 placental samples from 256 singleton pregnancies found no convincing evidence for the existence of a reproducible ‘preterm placental microbiome’ but did find evidence of *Mycoplasma* spp. and *Ureaplasma* spp. associated with PTB [95]. A further study from the Aagaard laboratory has shown that specifically,
preterm subjects with severe chorioamnionitis have high abundances of *Ureaplasma parvum, Fusobacterium nucleatum* and *Streptococcus agalactiae* within the placenta, supporting the idea of either ascending or haematogenous infection [96].

**The gut microbiome**

The gastrointestinal tract (GIT) has the largest surface area in the body that is exposed to foreign material consisting of a diverse community of fungi, protozoa, viruses, archaea and bacteria. The most abundant phyla of bacteria that exist in the human GIT are *Firmicutes*, *Bacteroidetes*, *Actinobacteria* and *Proteobacteria* with *Firmicutes* and *Bacteroidetes* occupying 70–90% of the total GIT bacteria [97, 98]. As many as 1000 species have been identified as having critical physiological roles that are essential to the host, including regulation of immune homeostasis. Evidence for this is supported by germ-free mice exhibiting an altered immune phenotype with deficits in the local innate and adaptive immune components [99, 100].

Several studies have sampled the gut microbiota across longitudinal timepoints in pregnancy as gestational age advances, with the majority reporting that the diversity and composition of bacterial communities remain largely stable throughout pregnancy [22, 97, 101]. However, the largest study of 91 women by Koren et al. showed a decrease in α-diversity and an expansion of β-inflammatory cytokine concentrations in stool [102]. They also describe an increase in the relative abundance of *Proteobacteria* and *Actinobacteria* in the third trimester in 69% and 57% of women respectively. OTUs overrepresented in the third trimester were of the *Enterobacteriaceae* family and *Streptococcus* genus, whereas OTUs overrepresented in the first trimester were the anti-inflammatory butyrate producers *Eubacterium* and *Faecalibacterium*. In addition, transfer of third trimester maternal microbiota to germ-free mice induced a mild inflammatory response, with higher stool IL-1β. It is therefore plausible that microbiome remodelling follows a distinct temporal adaptation in order to allow for gestational age–dependent immunomodulation to facilitate successful pregnancy and timely parturition.

The concept of both local and systemic temporal immune adaptation in healthy pregnancy is well-established. The beneficial anti-inflammatory state allows to accommodate the developing fetus during pregnancy, until a shift towards a pro-inflammatory state occurs in the third trimester to allow for parturition [103]. Given the evidence supporting the role of a systemic immunological clock in the timing of delivery, it is plausible that unfavourable and premature alterations in composition and diversity of the gut microbiota, resulting in systemic inflammation, could play a role in the aetiology of spontaneous preterm labour [104]. In addition, since there are close anatomical links between the lower reproductive tract and the lower intestinal tract, it is also plausible that microbial seeding between the gut and vagina can influence the microbial environment of both sites, leading to aberrant local inflammation.

Dahl et al. examined day 4 postpartum faecal samples from 19 women who delivered preterm and 102 women who delivered at term and revealed a reduction in α-diversity and lower operational taxonomic unit (OTU) abundances of the *Bifidobacterium* and *Streptococcus* genera, and of families in the *Clostridiales* order [105]. *Bifidobacterium* has many anti-inflammatory properties with multiple strains able to inhibit LPS-induced NF-κB activation, IL-8 and COX-2 production in vitro [106, 107]. Therefore, a reduction in *Bifidobacterium* could lead to increased susceptibility to inflammation/infection-induced preterm labour. Shiozaki et al. showed a reduction in OTUs from several species of *Clostridium* and *Bacteroides* in 10 women who delivered preterm compared with 10 women who delivered at term [108]. *Clostridia* spp. are potent inducers of T regulatory cell number and activation [109, 110]. *Bacteroides fragilis* promotes an anti-inflammatory response in the gut by activating IL-10 secreting T-reg cells via polysaccharide A. This suppresses the Toll-like receptor (TLR) 2 signalling pathway and dampens Th17 responses [111]. The authors elude to the alteration in gut microbial composition causing increased susceptibility to inflammation due to a reduction in T-reg cells, which is commonly reported in cases of PTB [112]. Whilst these studies provide some support for a potential role for gut microbial inflammation in mediating PTB risk, there is clearly the need for more investigation in this area [113, 114].

**Manipulation of vaginal microbiota to modify PTB risk**

Given that substantial evidence supports a link between specific vaginal microbiota composition and increased PTB risk, it is not surprising that numerous studies have examined the efficacy of antibiotics for the treatment and prevention PTB. These have almost entirely been targeted towards pregnant women with bacterial vaginosis (BV), and the results of these trials have proven highly inconsistent [115, 116]. In part, this is due to heterogeneity between trial designs (e.g. differences in the timing of treatment, types of antibiotic used, administration routes, patient cohorts selected and erroneous indications) [117, 118]. In the largest such trial to date, the double-blinded PREMEVA trial of oral clindamycin in early pregnancy [119] screened 85,000 women for BV with 1904 BV-positive participants (out of 5630 diagnosed) with low background risk for PTB assigned to the treatment arm and 956
participants assigned placebo consistent with the pre-trial defined 2:1 treatment:placebo ratio. No difference in the primary outcome of the composite of late miscarriage (16–21 weeks) or spontaneous very PTB (22–32 weeks) was detected between the two groups. Aspects of the PREMEVA trial design have come under scrutiny [117] [120], and there remain some experts who believe that a randomised, placebo-controlled trial of screening and treating BV in women with a history of PTB is still warranted [116]. However, there are a number of issues that need to be carefully considered in any such future trial. Treatment of women with existing BV implies that associated ascending infection or inflammatory pathway activation may have already commenced. Secondly, the use of some antibiotics (e.g. metronidazole) may cause lysing of bacteria and release of endotoxins [121], which are strong activators of inflammation in gestational tissues and therefore may potentiate an inflammatory phenotype [122–124]. Certain antibiotic treatments may be particularly effective against commensal species such as Lactobacillus, but not against pathogens associated with BV leading to inadvertent enrichment of these species in the vaginal niche [52, 125, 126]. Such trials would also need to be conducted with careful consideration of antibiotic resistance genes commonly found within BV-associated bacteria [127, 128]. The failure of antibiotic therapy to improve PTB in the context of abnormal vaginal flora, previous PTB or positive fetal fibronectin status has led to interest in the positive modulation of the vaginal microbiota using of live bio-therapeutic products (LBPs, live microorganisms, administered for the prevention or treatment of human disease) or probiotics (non-pathogenic microorganisms of human origin, given to provide health benefits). Probiotics may be given orally or less commonly vaginally. A systematic review of generally oral probiotic use in pregnancy found no evidence of any effect upon the PTB rate [129]. An observational study in Norway however found that probiotic milk consumption in early, but not mid to late pregnancy associates with a lower risk of PTB [130]. Two recently reported randomised controlled studies have found that oral probiotics, containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14, do not modify the vaginal microbiota in pregnancy [131] [132]. An alternative approach is direct vaginal administration of Lactobacillus LBP. L. crispatus has been shown to inhibit growth of Streptococcus agalactiae (group B streptococcus) in vitro. In non-pregnant women with a history of recurrent urinary tract infection, vaginal administration of L. crispatus following antibiotic treatment showed effective vaginal colonisation and a reduction in urinary tract infection recurrence [133]. Vaginal administration of both L. acidophilus and L. rhamnosus combined and L. crispatus has been shown a significantly reduced risk of recurrence in BV [134, 135]. Trials in pregnancy are currently in progress, but given the evidence for its protective effects, vaginal administration of suitable strains of L. crispatus represents a promising approach for beneficial modulation of the vaginal microbiota in pregnancy.

Conclusions

The introduction of high-throughput DNA sequencing techniques into microbiological research has confirmed what was previously known from culture-based classical microbiology and greatly expanded our ability to study communities of microorganisms. Whilst it is doubtful that a physiologically essential placental microbiome exists, it remains possible that some cases of preterm labour may be due to haematogenous spread of organisms to the placenta and uterus. Studying the role of the gut microbiota in pregnancy and the potential for gut microbial inflammation to be linked to PTB risk will be challenging, but could potentially be paradigm changing. The strongest evidence for the role of the microbiome in preterm birth relates to the vaginal microbiota. But there remain significant geographical and ethnic differences, the underlying mechanisms of which are yet unknown and whose elucidation will provide valuable insights into the mechanisms of preterm birth in different ethnic groups and communities. The most consistent finding across almost all studies is the benefit of a vaginal microbiota characterised by Lactobacillus crispatus. This opens the door to modulation through the use of live bio-therapeutic products.

Author contributions The manuscript was jointly written by all of the authors. All authors critically reviewed and approved the final version of the manuscript.

Funding information This work was supported by the March of Dimes European Preterm Birth Research Centre Funding and by the National Institute for Health Research Comprehensive Biomedical Research Centre at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the authors and not necessarily those of Imperial College, the NHS, the NIHR, the Department of Health or the March of Dimes.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, Cousens S, Mathers C, Black RE (2015) Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet 385(9966):430–440

2. Lamont RF (2003) Infection in the prediction and antibiotics in the prevention of spontaneous preterm labour and preterm birth. BJOG 110(Suppl 20):71–75

3. Lockwood CJ (2002) Predicting premature delivery—no easy task. N Engl J Med 346(4):282–284

4. Cotch MF, Pastorek JG 2nd, Nugent RP, Hillier SL, Gibbs RS, Martin DH, Eschenbach DA, Edelman R, Carey JC, Regan JA et al (1997) Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis 24(6):353–360

5. Gravett MG, Nelson HP, DeRouen T, Critchlow C, Eschenbach DA, Holmes KK (1986) Independent associations of bacterial vaginosis and Chlamydia trachomatis infection with adverse pregnancy outcome. JAMA 256(14):1899–1903

6. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JJ (2007) The human microbiome project. Nature 449(7164):804–810

7. Marchesi JR, Ravel J (2015) The vocabulary of microbiome research: a proposal. Microbiome 3:31

8. Chakravorty S, Helb D, Burday M, Connell N, Alland D (2007) A detailed analysis of 16S ribosomal RNA gene segments for the diagnosis of pathogenic bacteria. J Microbiol Methods 69(2):330–339

9. Pruski P, Lewis HV, Lee YS, Marchesi JR, Bennett PR, Takats Z, MacIntyre DA (2018) Assessment of microbiota-host interactions at the vaginal mucosa interface. Methods 149:74–84

10. Bachmann NL, Rockett RJ, Timms VJ, Sintchenko V (2018) Advances in clinical sample preparation for identification and characterization of bacterial pathogens using metagenomics. Front Public Health 6:363

11. MacIntyre DA, Sykes L, Bennett PR (2017) The human female urogenital microbiome: complexity in normality. Emerging Topics in Life Sciences 4(4):363–372

12. Hill GB, St Claire KK, Gutman LT (1995) Anaerobes predominate among the vaginal microflora of prepubertal girls. Clin Infect Dis 20(Suppl 2):S269–S270

13. Linhares IM, Summers PR, Larsen B, Giraldo PC, Witkin SS (2011) Contemporary perspectives on vaginal pH and lactobacillus. Am J Obstet Gynecol 204(2):120, e121–125

14. Hickey RJ, Zhou X, Pierson JD, Ravel J, Forney LJ (2012) Understanding vaginal microbiome complexity from an ecological perspective. Transl Res 160(4):267–282

15. Ravel J, Gajer P, Abdó Z, Schneider GM, Koening SS, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO et al (2011) Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 108(Suppl 1):4680–4687

16. Antonio MA, Rabe LK, Hillier SL (2005) Colonization of the rectum by Lactobacillus species and decreased risk of bacterial vaginosis. J Infect Dis 192(3):394–398

17. Eschenbach DA, Davick PR, Williams BL, Klebanoff SJ, Young-Smith K, Critchlow CM, Holmes KK (1989) Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 27(2):251–256

18. Ness RB, Hillier SL, Kip KE, Soper DE, Stamm CA, McGregor JA, Bass DC, Sweet RL, Rice P, Richter HE (2004) Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol 104(4):761–769

19. Wang S, Wang Q, Yang E, Yan L, Li T, Zhuang H (2017) Antimicrobial compounds produced by vaginal Lactobacillus crispatus are able to strongly inhibit Candida albicans growth, hyphal formation and regulate virulence-related gene expressions. Front Microbiol 8:564

20. Chaban B, Links MG, Jayaprakash TP, Wagner EC, Bourque DK, Lohn Z, Albert AY, van Schalkwyk J, Reid G, Hemmingsen SM et al (2014) Characterization of the vaginal microbiota of healthy Canadian women through the menstrual cycle. Microbiome 2:23

21. Roy EJ, Mackay R (1962) The concentration of oestrogens in blood during pregnancy. J Obstet Gynaecol Br Emp 69:13–17

22. DiGiulio DB, Callahan BJ, McMurdie PJ, Costello EK, Lyrell DJ, Robaczewska A, Sun CL, Goldtsman DS, Wong RJ, Shaw G et al (2015) Temporal and spatial variation of the human microbiota during pregnancy. Proc Natl Acad Sci U S A 112(35):11060–11065

23. Goldenberg RL, Culhane JF, Iams JD, Romero R (2008) Epidemiology and causes of preterm birth. Lancet 371(9606):75–84

24. Romero R, Gomez R, Chaiworapongs S, Conoscenti G, Kim JC, Kim YM (2001) The role of infection in preterm labour and delivery. Paediatr Perinat Epidemiol 15(Suppl 2):41–56

25. Benirschke K (1960) Routes and types of infection in the fetus and neonate. Paediatr Perinat Epidemiol 15(Suppl 2):41–56

26. Jones HE, Harris KA, Azizia M, Bank L, Carpenter B, Hartley JC, Klein N, Peebles D (2009) Differing prevalence and diversity of bacterial species in fetal membranes from very preterm and term labor. PLoS One 4(12):e8205

27. Romero R, Sirota M, Oyarzun E, Avila C, Mazor M, Callahan R, Sabo V, Athanassiadis AP, Hobbins JC (1989) Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes. Am J Obstet Gynecol 161(3):817–824

28. Romero R, Shamma F, Avila C, Jimenez C, Callahan R, Nores J, Mazor M, Brekus CA, Hobbins JC (1990) Infection and labor. VI. Prevalence, microbiology, and clinical significance of intraamniotic infection in twin gestations with preterm labor. Am J Obstet Gynecol 163(3):757–761

29. Suff N, Karda R, Diaz JA, Ng J, Baruteau J, Perocheau D, Tangney M, Taylor PW, Peebles D, Buckley SMK et al (2018) Ascending vaginal infection using bioluminescent bacteria evokes intrauterine inflammation, preterm birth, and neonatal brain injury in pregnant mice. Am J Pathol 188(10):2164–2176

30. Akgul Y, Word RA, Ensing LM, Yamaguchi Y, Lydon J, Hanes J, Mahendroo M (2014) Hyaluronan in cervical epithelia protects against infection-mediated preterm birth. J Clin Invest 124(12):5481–5489

31. Randis TM, Gelber SE, Hooven TA, Abellar RG, Akbaras LB, Lewis EL, Walker LB, Byland LM, Nizet V, Ratner AJ (2014) Group B Streptococcus beta-hemolysin/cytolysin breaches maternal-fetal barriers to cause preterm birth and intrauterine fetal demise in vivo. J Infect Dis 210(2):265–273

32. Racicot K, Cardenas I, Wunsche V, Aldo P, Guller S, Means RE, Taylor PW, Peebles D, Buckley SMK et al (2018) Ascending vaginal infection using bioluminescent bacteria evokes intrauterine inflammation, preterm birth, and neonatal brain injury in pregnant mice. Am J Pathol 188(10):2164–2176

33. Vornhagen J, Quach P, Boldenow E, Merillat S, Whidbey C, Ngy LY, Adams Waldorf KM, Rajagopal L (2016) Bacterial hyaluronidase promotes ascending GBS infection and preterm birth. MBio, 7(3)

34. Vornhagen J, Armstead B, Santana-Ufret V, Gendrin C, Merillat S, Coleman M, Quach P, Boldenow E, Alishetti V, Leonhardt-Melief C et al (2018) Group B streptococcus exploits vaginal epithelial exfoliation for ascending infection. J Clin Invest 128(5):1985–1999
35. Hyman RW, Fukushima M, Jiang H, Fung E, Rand L, Johnson B, Vo KC, Caughey AB, Hilton JF, Davis RW et al (2014) Diversity of the vaginal microbiome correlates with preterm birth. Reprod Sci 21(1):32–40
36. Romero R, Hassan SS, Gajer P, Tarca AL, Fadros DW, Bieda J, Chaeamthong P, Miranda J, Chaivoraphongsa T, Ravel J (2014) The vaginal microbiota of pregnant women who subsequently have spontaneous preterm labor and delivery and those with a normal delivery at term. Microbiome 2:18
37. Callahan BJ, DiGiulio DB, Goldtsman DSA, Sun CL, Costello EK, Jeganathan P, Biggio JR, Wong RJ, Druzin ML, Shaw GM et al (2017) Replication and refinement of a vaginal microbial signature of preterm birth in two racially distinct cohorts of US women. Proc Natl Acad Sci U S A 114(37):9966–9971
38. Nelson DB, Shin H, Wu J, Dominguez-Bello MG (2016) The gestational vaginal microbiome and spontaneous preterm birth among nulliparous African American women. Am J Perinatol 33(9):887–893
39. Stout MJ, Zhou Y, Wylie KM, Terr PI, Macones GA, Tuuli MG (2017) Early pregnancy vaginal microbiome trends and preterm birth. Am J Obstet Gynecol, 217(3):356 e351–356 e318
40. Elvovitz MA, Gajer P, Riis V, Brown AG, Humphrys MS, Holm JB, Ravel J (2019) Cervicovaginal microbiota and local immune modulation modulate the risk of spontaneous preterm delivery. Nat Commun 10(1):1305
41. Fettweis JM, Serrano MG, Brooks JP, Edwards DJ, Girerd PH, Parikh HI, Huang B, Arodz TJ, Edupuganti L, Glasscock AL et al (2019) The vaginal microbiome and preterm birth. Nat Med 25(6):1012–1021
42. Petricic L, Domig KJ, Nierscher FJ, Sandhofer MJ, Fidesser M, Kron dorfer I, Husslein P, Kniefel W, Kiss H (2014) Characterisation of the vaginal Lactobacillus microbiota associated with preterm delivery. Sci Rep 4:5136
43. Kindinger LM, Bennett PR, Lee YS, Marchesi JR, Smith A, Cacciatoro S, Holmes E, Nicholson JK, Teoh TG, Maclntyre DA (2017) The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk. Microbiome 5(1):6
44. Tabatabaei N, Eren AM, Barreiro LB, Yotova V, Dumaine A, Allard C, Fraser WD (2019) Vaginal microbiome in early pregnancy and subsequent risk of spontaneous preterm birth: a case-control study. BJOG 126(3):349–358
45. Parry S, Strauss JF 3rd (1998) Premature rupture of the fetal membranes. N Engl J Med 338(10):663–670
46. Lu H, Wang Q, Lu J, Zhang Q, Kumar P (2016) Risk factors for intraventricular hemorrhage in preterm infants born at 34 weeks of gestation. J Stroke Cerebrovasc Dis 25(4):807–812
47. Pur F, Tait DH, Ambalavanan N, Schiller KR, Morrow AL, Kallapur SG (2016) Association of chorioamnionitis with aberrant neonatal gut colonization and adverse clinical outcomes. PLoS One 11(9):e0162734
48. Rocha G, Proenca E, Quintas C, Rodrigues T, Guimarães H (2007) Chorioamnionitis and brain damage in the preterm newborn. J Matern Fetal Neonatal Med 20(10):745–749
49. Baldwin EA, Walther-Antonio M, MacLean AM, Gohl DM, Beckman KB, Chen J, White B, Creedon DJ, Chia N (2015) Persistent microbial dysbiosis in preterm premature rupture of membranes from onset until delivery. PeerJ 3:e1398
50. Vescicki P, Kacerovsky Musilova I, Stranik J, Stepan M, Kacerovsky M (2020) Lactobacillus crispatus dominant vaginal microbiota in pregnancy. Ceska Gynekol 85(1):67–71
51. Paramel Jayaprakash T, Wagner EC, van Schalkwyk J, Albert AH, Hill JE, Money DM, Group PS (2016) High diversity and variability in the vaginal microbiome in women following preterm premature rupture of membranes (PPROM): a prospective cohort study. PLoS One 11(1):e0166794
52. Brown RG, Marchesi JR, Lee YS, Smith A, Lehne B, Kindinger LM, Terzidou V, Holmes E, Nicholson JK, Bennett PR et al (2018) Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin. BMC Med 16(1):9
53. Brown RG, Al-Memar M, Marchesi JR, Lee YS, Smith A, Chan D, Lewis H, Kindinger L, Terzidou V, Bourne T et al (2019) Establishment of vaginal microbiota composition in early pregnancy and its association with subsequent preterm prelabour rupture of the fetal membranes. Transl Res 207:30–43
54. Carbonne B, Dallot E, Haddad B, Ferre F, Cabrol D (2000) Effects of progesterone on prostaglandin E(2)-induced changes in glycosaminoglycan synthesis by human cervical fibroblasts in culture. Mol Hum Reprod 6(7):661–664
55. Hardy DB, Janowski BA, Corey DR, Mendelson CR (2006) Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-kappaB activation of cyclooxygenase 2 expression. Mol Endocrinol 20(11):2724–2733
56. Loudon JA, Elliott CL, Hills F, Bennett PR (2003) Progesterone represses interleukin-8 and cyclo-oxygenase-2 in human lower segment fibroblasts and amnion epithelial cells. Biol Reprod 69(1):331–337
57. Anderson L, Martin W, Higgins C, Nelson SM, Norman JE (2009) The effect of progesterone on myometrial contractility, potassium channels, and tocolytic efficacy. Reprod Sci 16(11):1052–1061
58. Nold C, Maubert M, Anton L, Yellon S, Elovitz MA (2013) Prevention of preterm birth by progestational agents: what are the molecular mechanisms? Am J Obstet Gynecol, 208(3):223 e221–227
59. Yellon SM, Dobyns AE, Beck HL, Kurtzman JT, Garfield RE, Kirby MA (2013) Loss of progesterone receptor-mediated actions induce preterm cellular and structural remodeling of the cervix and premature birth. PLoS One 8(12):e81340
60. Chandiramani M, Seed PT, Orsi NM, Ekbote UV, Bennett PR, Shennan AH, Tribe RM (2012) Limited relationship between cervico-vaginal fluid cytokine profiles and cervical shortening in women at high risk of spontaneous preterm birth. PLoS One 7(12):e52412
61. Borgdorff H, Tsivtsivadze E, Verwijs MC, Wit FW, Tsivtsivadze E, Verhelst R, Marzorati M, Jurriaans S, Ndayisaba GF, Verhelst R, Schuren FH, van de Wijgert JH (2015) The impact of hormonal contraception and pregnancy on sexually transmitted infections and on cervicovaginal microbiota in African women. ISME J 8(7):1781–1793
62. Borgdorff H, Verwijs MC, Wit FW, Tsivtsivadze E, Ndayisaba GF, Verhelst R, Schuren FH, van de Wijgert JH (2015) The impact of hormonal contraception and pregnancy on sexually transmitted infections and on cervicovaginal microbiota in African sex workers. Sex Transm Dis 42(3):143–152
63. Ralph LJ, Gollub EL, Jones HE (2015) Hormonal contraceptive use and women’s risk of HIV acquisition: priorities emerging from recent data. Curr Opin Obstet Gynecol 27(6):487–495
64. Althuisius SM, Dekker GA, Hummel P, van Geijn HP (2003) Establishment of vaginal microbiota composition in early pregnancy and its association with subsequent preterm prelabour rupture of the fetal membranes. Transl Res 207:30–43
65. Gundabattula SR, Marakani LR, Dasari S, Surampudi K, Pochiraju M, Nirmalan PK (2013) Outcomes of pregnancy in women who had rescue cerclage for cervical insufficiency: a single-center retrospective study. J Obstet Gynaecol Res 39(8):1293–1300
66. Pereira L, Cotter A, Gomez R, Berghella V, Prasertcharoenkus W, Rasane J, Chaithongwongwatthana S, Mittal S, Daly S, Airoldi J
et al (2007) Expectant management compared with physical examination-indicated cerclage (EM-PEC) in selected women with a dilated cervix at 14(0/7)-25(6/7) weeks: results from the EM-PEC international cohort study. Am J Obstet Gynecol 197(5): e483 e488–488

67. Ventolini G, Genrich TJ, Roth J, Neiger R (2009) Pregnancy outcome after placement of ‘rescue’ Shirodkar cerclage. J Perinatol 29(4):276–279

68. Brown RG, Chan D, Terzidou V, Lee YS, Smith A, Marchesi JR, MacIntyre DA, Bennett PR (2019) Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage. BJOG 126(7):916–925

69. Kyrgiou M, Valasoulis G, Stasinou SM, Founta C, Athanasiou A, Bennett P, Paraskevadis E (2015) Proportion of cervical excision for cervical intraepithelial neoplasia as a predictor of pregnancy outcomes. Int J Gynaecol Obstet 128(2):141–147

70. Mitra A, MacIntyre DA, Lee YS, Smith A, Marchesi JR, Lehne B, Bhatia R, Lyons D, Paraskevadis E, Li JV et al (2015) Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci Rep 5:16865

71. Mitra A, MacIntyre DA, Ntitsos G, Smith A, Tsilidis KK, Marchesi JR, Bennett PR, Moscicki AB, Kyrgiou M (2020) The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions. Nat Commun 11(1):1999

72. Wiik J, Sengpiel V, Kyrgiou M, Nilsson S, Mitra A, Tanbo T, Monceyon Jonassen C, Moller Tamaaes T, Sjoberg K (2019) Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study. BMC Womens Health 19(1):30

73. Zhang H, Lu J, Lu Y, Cai Q, Liu H, Xu C (2018) Cervical microbiome is altered in cervical intraepithelial neoplasia after loop electrosurgical excision procedure in China. Scp Rep 8(1): 4923

74. Kindinger LM, Kyrgiou M, MacIntyre DA, Cacciatore S, Yulia A, Cook J, Terzidou V, Teoh TG, Bennett PR (2016) Preterm birth prevention: a model of cervical length screening with targeted cerclage. PLoS One 11(11):e0163793

75. Witkin SS, Mendes-Soares H, Linhares IM, Jayaram A, Ledger WM-PEC international cohort study. Am J Obstet Gynecol 197(5): e141–e148

76. Amabebe E, Anumba DOC (2018) The vaginal microenvironment: the physiologic role of lactobacilli. Front Med (Lausanne) 5:181

77. Petrova MI, Reid G, Vaneechoutte M, Lebeer S (2017) Lactobacillus iners: friend or foe? Trends Microbiol 25(3):182–191

78. Kindinger LM, MacIntyre DA, Lee YS, Marchesi JR, Smith A, McDonald JA, Terzidou V, Cook JR, Lees C, Israeli-Bayil F et al (2016) Relationship between vaginal microbial dysbiosis, inflammation, and pregnancy outcomes in cervical cerclage. Sci Transl Med 8(350):350ra102

79. Menon R, Yu J, Basanta-Henry P, Brou L, Berga SL, Fortunato SJ, Taylor RN (2012) Short fetal leukocyte telomere length and preterm prelabor rupture of the membranes. PLoS One 7(2): e31136

80. Mendz GL, Kaakoush NO, Quinlivan JA (2013) Bacterial aetiological agents of intra-amniotic infections and preterm birth in pregnant women. Front Cell Infect Microbiol 3:58

81. Cobb CM, Kelly PJ, Williams KB, Babbar S, Angolkar M, Derman RJ (2017) The oral microbiome and adverse pregnancy outcomes. Int J Women's Health 9:551–559

82. Han YW, Redline RW, Li M, Yin L, Hill GB, McCormick TS (2004) Fusobacterium nucleatum induces premature and term stillbirths in pregnant mice: implication of oral bacteria in preterm birth. Infect Immun 72(4):2272–2279

83. Fardini Y, Chung P, Dumm R, Joshi N, Han YW (2010) Transmission of diverse oral bacteria to murine placenta: evidence for the oral microbiome as a potential source of intrauterine infection. Infect Immun 78(4):1789–1796

84. Chaim W, Mazor M (1992) Intraamniotic infection with fusobacteria. Arch Gynecol Obstet 251(1):1–7

85. Offenbacher S, Oettinger-Barak O, Machtei EE, Sprecher H, Ohel G (2007) Evidence of periopathogenic microorganisms in placentas of women with preeclampsia. J Periodontol 78(4):670–676

86. Offenbacher S, Katz V, Fertik G, Collins J, Boyd D, Maynor G, McKaig R, Beck J (1996) Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol 67(10 Suppl): 1103–1113

87. Pattanashetti JI, Nagathan VM, Rao SM (2013) Evaluation of periodontitis as a risk for preterm birth among preeclamptic and non-preeclamptic pregnant women - a case control study. J Clin Diagn Res 7(8):1776–1778

88. Michalowicz BS, Hodges JS, DiAngelis AJ, Lupo VR, Novak MJ, Ferguson JE, Buchanan W, Bofill J, Papapanou PN, Mitchell DA et al (2006) Treatment of periodontal disease and the risk of preterm birth. N Engl J Med 355(18):1885–1894

89. Offenbacher S, Beck JD, Jared HL, Mauriello SM, Mendoza LC, Couper DJ, Stewart DD, Murtha AP, Cochran DL, Dudley DJ et al (2009) Effects of periodontal therapy on rate of preterm delivery: a randomized controlled trial. Obstet Gynecol 114(3):551–559

90. Macones GA, Parry S, Nelson DB, Strauss JF, Ludmir J, Cohen AW, Stamilo DM, Appleby D, Clothier B, Sammel MD et al (2010) Treatment of localized periodontal disease in pregnancy does not reduce the occurrence of preterm birth: results from the Periodontal Infections and Prematurity Study (PIPS). Am J Obstet Gynecol 202(2):e141–e148

91. Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J (2014) The placenta harbors a unique microbiome. Sci Transl Med 6(237):237ra265

92. Laufer AP, Roche AM, Sherrill-Mix S, Bailey A, Laughlin AL, Bittinger K, Leite R, Ellowitz MA, Parry S, Bushman FD (2016) Comparison of placenta samples with contamination controls does not provide evidence for a distinct placenta microbiota. Microbiome 4(1):29

93. Theis KR, Romero R, Winters AD, Greenberg JM, Gomez-Lopez N, Alhouseini A, Bieda J, Maymon E, Pacora P, Fettweis JM et al (2019) Does the human placenta delivered at term have a microbiota? Results of cultivation, quantitative real-time PCR, 16S rRNA gene sequencing, and metagenomics. Am J Obstet Gynecol, 220(3):267 e261–267 e239

94. de Goffau MC, Lager S, Sovio U, Gaccioli F, Cook E, Peacock E, Parkhill J, Charnock-Jones DS, Smith GCS (2019) Human placenta has no microbiome but can contain potential pathogens. Nature 572(7769):329–334

95. Leon LJ, Doyle R, Dzie-Benavente E, Clark TG, Klein N, Stanier P, Moore GE (2018) Enrichment of clinically relevant organisms in spontaneous preterm-delivered placentas and reagent contamination across all clinical groups in a large pregnancy cohort in the United Kingdom. Appl Environ Microbiol, 84(14)

96. Prince AL, Ma J, Kannan PS, Alvarez M, Gisslen T, Harris RA, Couper DJ, Stewart DD, Murtha AP, Cochran DL, Dudley DJ et al (2009) Effects of periodontal therapy on rate of preterm delivery: a randomized controlled trial. Obstet Gynecol 114(3):551–559

97. Avershina E, Rudi K, Narbad A, Jenmalm MC et al (2015) The phy of the bacterial microbiota. Nat Rev Microbiol 14(1):20–32

98. Rodriguez JM, Murphy K, Mazor M, Ramirez-Lopez N, Alhouseini A, Bieda J, Maymon E, Pacora P, Fettweis JM et al (2019) Does the human placenta delivered at term have a microbiota? Results of cultivation, quantitative real-time PCR, 16S rRNA gene sequencing, and metagenomics. Am J Obstet Gynecol, 220(3):267 e261–267 e239

99. de Goffau MC, Lager S, Sovio U, Gaccioli F, Cook E, Peacock E, Parkhill J, Charnock-Jones DS, Smith GCS (2019) Human placenta has no microbiome but can contain potential pathogens. Nature 572(7769):329–334

100. Leon LJ, Doyle R, Dzie-Benavente E, Clark TG, Klein N, Stanier P, Moore GE (2018) Enrichment of clinically relevant organisms in spontaneous preterm-delivered placentas and reagent contamination across all clinical groups in a large pregnancy cohort in the United Kingdom. Appl Environ Microbiol, 84(14)

101. Prince AL, Ma J, Kannan PS, Alvarez M, Gisslen T, Harris RA, Couper DJ, Stewart DD, Murtha AP, Cochran DL, Dudley DJ et al (2009) Effects of periodontal therapy on rate of preterm delivery: a randomized controlled trial. Obstet Gynecol 114(3):551–559

102. Avershina E, Rudi K, Narbad A, Jenmalm MC et al (2015) The phy of the bacterial microbiota. Nat Rev Microbiol 14(1):20–32

103. Rodriguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, Narbad A, Jenmalm MC et al (2015) The
composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis 26:26050

99. Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Glickman JN, Siebert R, Baron RM, Kasper DL et al (2012) Microbial exposure during early life has persistent effects on natural killer T cell function. Science 336(6080):489–493

100. Wesemann DR, Portuguese AJ, Meyers RM, Gallagher MP, Cluff-Jones K, Magee JM, Panchakshari RA, Rodig SJ, Kepler TB, Alt FW (2013) Microbial colonization influences early B-lineage development in the gut lamina propria. Nature 501(7465):112–115

101. Dunlop AL, Knight AK, Satten GA, Cutler AJ, Wright ML, Mitchell RM, Read TD, Mulle J, Hertzberg VS, Hill CC et al (2019) Stability of the vaginal, oral, and gut microbiota across pregnancy among African American women: the effect of socioeconomic status and antibiotic exposure. PeerJ 7:e6004

102. Koren O, Goodrich JK, Cullender TC, Spor A, Latinen K, Backhed HK, Gonzalez A, Werner JI, Angenent LT, Knight R et al (2012) Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell 150(3):470–480

103. Mor G, Aldo P, Alvero AB (2017) The unique immunological and microbiotal aspects of pregnancy. Nat Rev Immunol 17(8):469–482

104. Aghaeepour N, Ganio EA, McIlwain D, Tsai AS, Tingle M, Van Wesemann DR, Portuguese AJ, Meyers RM, Gallagher MP, Olszak T, And, Zeissig S, Vera MP, Richter J, Frank E (2019) Microbial aspects of pregnancy. Nat Rev Immunol 17(8):469–482

105. Dahl C, Stanislawski M, Iszatt N, Mandal S, Lozupone C, Koren O, Goodrich JK, Kurth S, Utzinger J, Workowski K, Conde-Agudelo A, Romero R (2011) Bifidobacteria and their molecular communication with indigenous Y, Cheng G, Yamasaki S, Saito T, Ohba Y et al (2011) Induction of colonic regulatory T cells by indigenous Microbiota and Streptococcus. PLoS One 12(10):e0184336

106. Riedel CU, Foata F, Philippe D, Adolfsen O, Eikmanns BJ, Blum S (2006) Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. World J Gastroenterol 12(23):3729–3735

107. Ruiz L, Delgado S, Gallagher MP, Cluff-Jones K, Magee JM, Panchakshari RA, Rodig SJ, Kepler TB, Alt FW (2013) Microbial colonization influences early B-lineage development in the gut lamina propria. Nature 501(7465):112–115

108. Shiozaki A, Yoneda S, Yoneda N, Yonezawa R, Matsubayashi T, Arenas-Hernandez M (2014) Immune cells in term and preterm labor. Cell Mol Immunol 11(6):571–581

109. Round JL, Mazmanian SK (2009) The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9(5):313–323

110. Gomez-Lopez N, StLouis D, Lehr MA, Sanchez-Rodriguez EN, Arenas-Hernandez M (2014) Immune cells in term and preterm labor. Cell Mol Immunol 11(6):571–581

111. Brummaier T, Syed Aahmed Kabeer B, Lindow S, Konje JC, Pukrittayakamee S, Uzinger J, Toufiq M, Antoniou A, Marr AK, Suriyakan S et al (2019) A prospective cohort for the investigation of alteration in temporal transcriptional and microbiome trajectories preceding preterm birth: a study protocol. BMJ Open 9(1):e023417

112. Corwin EJ, Hogue CJ, Pearce B, Hill CC, Read TD, Mulle J, Dunlop AL (2017) Protocol for the Emory University African American Vaginal, Oral, and Gut Microbiome in Pregnancy Cohort Study. BMC Pregnancy Childbirth 17(1):161

113. Lamont RF, Nhan-Chang CL, Sobel JD, Workowski KJ, Conde-Agudelo A, Romero R (2011) Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 205(3):177–190

114. Brocklehurst P, Gordon A, Heatley E, Miljan SJ (2013) Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 1:CD00262

115. Lamont RF (2019) Spontaneous preterm labour that leads to preterm birth: an update and personal reflection. Placenta 79:21–29

116. Lamont RF, Keelan JA, Larsson PG, Jorgensen JS (2017) The treatment of bacterial vaginosis in pregnancy with clindamycin to reduce the risk of infection-related preterm birth: a response to the Danish Society of Obstetrics and Gynecology guideline group’s clinical recommendations. Acta Obstet Gynecol Scand 96(2):139–143

117. Subtil D, Brabant G, Tilloy E, Devos P, Canis F, Fruchart A, Bissinger MC, Dugimont JC, Nolf C, Hacot C et al (2018) Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. Lancet 392(10160):2171–2179

118. Klebanoff MA, Brotman RM (2018) Treatment of bacterial vaginosis to prevent preterm birth. Lancet 392(10160):2141–2142

119. Morency AM, Bujold E (2007) The effect of second-trimester antibiotic therapy on the rate of preterm birth. J Obstet Gynaecol Can 29(1):35–44

120. Migale R, Herbert BR, Lee YS, Sykes L, Waddington SN, Peebles D, Hagberg H, Johnson MR, Bennett PR, MacIntyre DA (2015) Specific lipopolysaccharide serotypes induce differential maternal and neonatal inflammatory responses in a murine model of preterm labor. Am J Pathol 185(9):2390–2401

121. MacIntyre DA, Lee YS, Migale R, Herbert BR, Waddington SN, Peebles D, Hagberg H, Johnson MR, Bennett PR (2014) Activator protein 1 is a key terminal mediator of inflammation-induced preterm labor in mice. FASEB J 28(5):2358–2368

122. MacIntyre DA, Sykes L, Teoh TG, Bennett PR (2012) Prevention of preterm labor via the modulation of inflammatory pathways. J Matern Fetal Neonatal Med 25(Suppl 1):17–20

123. Ferris MJ, Masztal A, Aldridge KE, Fortenberry JD, Fidel PL Jr, Martin DH (2004) Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis 4:5

124. Lamont RF (2015) Advances in the prevention of infection-related preterm birth. Front Immunol 6:566

125. Bostwick DG, Woody J, Hunt C, Budd W (2016) Antimicrobial resistance genes and modelling of treatment failure in bacterial vaginosis: clinical study of 289 symptomatic women. J Med Microbiol 65(5):377–386

126. Beigi RH, Austin MN, Meyn LA, Krohn MA, Hillier SL (2004) Antimicrobial resistance associated with the treatment of bacterial vaginosis: clinical study of 289 symptomatic women. J Med Microbiol 53(5):377–386
130. Nordqvist M, Jacobsson B, Brantsaeter AL, Myhre R, Nilsson S, Sengpiel V (2018) Timing of probiotic milk consumption during pregnancy and effects on the incidence of preeclampsia and preterm delivery: a prospective observational cohort study in Norway. BMJ Open 8(1):e018021

131. Husain S, Allotey J, Drymoussi Z, Wilks M, Fernandez-Felix BM, Whiley A, Dodds J, Thangaratinam S, McCourt C, Prosdocimi EM et al (2020) Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis. BJOG 127(2): 275–284

132. Yang S, Reid G, Challis JRG, Gloor GB, Asztalos E, Money D, Seney S, Bocking AD (2020) Effect of oral probiotic *Lactobacillus rhamnosus* GR-1 and *Lactobacillus reuteri* RC-14 on the vaginal microbiota, cytokines and chemokines in pregnant women. Nutrients, 12(2)

133. Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, Yarova-Yarovaya Y, Fiedler T, Cox M, Stamm WE (2011) Randomized, placebo-controlled phase 2 trial of a *Lactobacillus crispatus* probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 52(10): 1212–1217

134. Cohen CR, Wierzbicki MR, French AL, Morris S, Newmann S, Reno H, Green L, Miller S, Powell J, Parks T et al (2020) Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med 382(20):1906–1915

135. Russo R, Karadja E, De Seta F (2019) Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. Benef Microbes 10(1):19–26

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.